Related Experiment Videos
Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases
1Department of Pathology, Medical College of Pennsylvania, Philadelphia 19129.
Abstract:
We have examined the antimetastatic effects of taxol on a PC-3 human prostatic tumor variant (PC-3 ML) which metastasizes to the lumbar vertebrae in severe combined immunodeficiency-carrying (SCID) mice. Immunofluorescence labeling indicated that taxol (0.5 to 1.0 microM for 6 h) produced an abnormal bundling of microtubules in a dosage-dependent manner. Slot blotting and gelatinase assays revealed that taxol inhibited secretion of the M(r) 72,000 and M(r) 92,000 type IV collagenases plus a M(r) 57,000 gelatinase. Radioimmunoprecipitation measurements confirmed that the drug inhibited both the secretion and the synthesis of the M(r) 72,000 collagenase. Taxol also blocked total protein secretion but did not influence total protein synthesis or turnover. Boyden chamber chemotactic studies further showed that taxol (0.5 to 1.0 microM) inhibited invasion of Matrigel. More importantly, studies in SCID mice demonstrated that taxol (50 to 250 mg/m2/day) blocked the establishment, growth, and long-term survival of PC-3 ML cells.
Insights
Taxol demonstrated significant antimetastatic effects against human prostate cancer cells in mice. This chemotherapy agent inhibited tumor cell invasion and growth by affecting microtubules and collagenase secretion.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Prostate cancer metastasis remains a significant clinical challenge.
- Understanding the molecular mechanisms of metastasis is crucial for developing effective therapies.
- Taxol (paclitaxel) is a well-known chemotherapy agent with microtubule-stabilizing properties.
Purpose of the Study:
- To investigate the antimetastatic effects of Taxol on a metastatic variant of human prostate cancer (PC-3 ML) in severe combined immunodeficiency (SCID) mice.
- To elucidate the molecular mechanisms underlying Taxol's antimetastatic action.
Main Methods:
- Immunofluorescence labeling to assess microtubule dynamics.
- Slot blotting and gelatinase assays to measure collagenase activity.
- Radioimmunoprecipitation to evaluate protein synthesis and secretion.
- Boyden chamber assays to determine cell invasion.
- In vivo studies using SCID mice xenograft model.
Main Results:
- Taxol induced abnormal microtubule bundling in a dose-dependent manner.
- Taxol inhibited the secretion and synthesis of M(r) 72,000 and M(r) 92,000 type IV collagenases and a M(r) 57,000 gelatinase.
- The drug blocked total protein secretion but not synthesis or turnover.
- Taxol significantly inhibited PC-3 ML cell invasion through Matrigel.
- In vivo, Taxol treatment blocked the establishment, growth, and survival of PC-3 ML tumors in SCID mice.
Conclusions:
- Taxol exhibits potent antimetastatic properties against human prostate cancer.
- Its mechanisms involve disruption of microtubule organization and inhibition of key matrix metalloproteinases involved in invasion.
- Taxol effectively suppresses tumor establishment, growth, and survival in a preclinical model.